{"id":409412,"date":"2021-01-06T08:04:20","date_gmt":"2021-01-06T13:04:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=409412"},"modified":"2021-01-06T08:04:20","modified_gmt":"2021-01-06T13:04:20","slug":"arcturus-therapeutics-to-present-at-upcoming-investor-conference-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\/","title":{"rendered":"Arcturus Therapeutics to Present at Upcoming Investor Conference"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Arcturus Therapeutics to Present at Upcoming Investor Conference<\/b><\/p>\n<p>SAN DIEGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nArcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in a panel discussion taking place at the 13<sup>th<\/sup> Annual Biotech Showcase\u2122 Investor Conference:\n<\/p>\n<p><b>Infectious Disease &#8211;<\/b><b>COVID-19 Vaccines: All things impacted by COVID-19: The pursuit for an effective vaccine developed at a pandemic pace<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nPanel Discussion\n<\/li>\n<li>\nDate: Monday, Jan 11, 2020\n<\/li>\n<li>\nTime: 1:00 p.m. ET, on-demand Jan 12-March 31 on the event\u2019s platform, partneringONE\n<\/li>\n<li><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finformaconnect.com%2Fbiotech-showcase%2Fagenda%2F7%2F%23biotech-showcase_live-session-infectious-disease-covid-19-vaccines-all-things-impacted-by-covid-19-the-pursuit-for-an-effective-vaccine-developed-at-a-pandemic-pace_10-00am&amp;esheet=52357205&amp;newsitemid=20210106005325&amp;lan=en-US&amp;anchor=Conference+Link&amp;index=1&amp;md5=731476ac6180c1fe3499d8481a63372f\">Conference Link<\/a><\/li>\n<\/ul>\n<p><strong>About Arcturus Therapeutics<\/strong><\/p>\n<p>\nFounded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR\u00ae lipid-mediated delivery, (ii) STARR\u2122 mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus\u2019 diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, and Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus\u2019 versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus\u2019 technologies are covered by its extensive patent portfolio (205 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus\u2019 commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation. For more information visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ArcturusRx.com&amp;esheet=52357205&amp;newsitemid=20210106005325&amp;lan=en-US&amp;anchor=www.ArcturusRx.com&amp;index=2&amp;md5=7149ce74a7929cb24a0c0b113658d6a7\">www.ArcturusRx.com<\/a>. In addition, please connect with us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FArcturusRx&amp;esheet=52357205&amp;newsitemid=20210106005325&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=a903ed5dc0538c54469a1d13e97db7c1\">Twitter<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Farcturus-therapeutics&amp;esheet=52357205&amp;newsitemid=20210106005325&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=f6ef1b219276beccab85419e3566ab8a\">LinkedIn<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210106005325r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210106005325\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210106005325\/en\/<\/a><\/span><\/p>\n<p><b>IR and Media Contacts<\/b><\/p>\n<p>\nArcturus Therapeutics<br \/>\n<br \/>Neda Safarzadeh<br \/>\n<br \/>(858) 900-2682<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:IR@ArcturusRx.com\">IR@ArcturusRx.com<\/a><\/p>\n<p>\nKendall Investor Relations<br \/>\n<br \/>Carlo Tanzi, Ph.D.<br \/>\n<br \/>(617) 914-0008<br \/>\n<br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DUxSgwei_MHF6Q_VeMHd_py87PYvRHu1jMGxIN2kKlRqWnT5kWNXbfnAJqvf-7n29LJyZypFQhqttbrYU_EryTbrNNtMGxSrceOqEqiq8mEU%3D&amp;esheet=52357205&amp;newsitemid=20210106005325&amp;lan=en-US&amp;anchor=ctanzi%40kendallir.com&amp;index=5&amp;md5=191f09100339540fdf76a6d486fc96c9\">ctanzi@kendallir.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> General Health Health Science Pharmaceutical Research<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210106005325\/en\/850516\/3\/arcturus-logo-blueback.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Arcturus Therapeutics to Present at Upcoming Investor Conference SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Arcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in a panel discussion taking place at the 13th Annual Biotech Showcase\u2122 Investor Conference: Infectious Disease &#8211;COVID-19 Vaccines: All things impacted by COVID-19: The pursuit for an effective vaccine developed at a pandemic pace Panel Discussion Date: Monday, Jan 11, 2020 Time: 1:00 p.m. ET, on-demand Jan 12-March 31 on the event\u2019s platform, partneringONE Conference Link About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Arcturus Therapeutics to Present at Upcoming Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-409412","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arcturus Therapeutics to Present at Upcoming Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arcturus Therapeutics to Present at Upcoming Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Arcturus Therapeutics to Present at Upcoming Investor Conference SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Arcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in a panel discussion taking place at the 13th Annual Biotech Showcase\u2122 Investor Conference: Infectious Disease &#8211;COVID-19 Vaccines: All things impacted by COVID-19: The pursuit for an effective vaccine developed at a pandemic pace Panel Discussion Date: Monday, Jan 11, 2020 Time: 1:00 p.m. ET, on-demand Jan 12-March 31 on the event\u2019s platform, partneringONE Conference Link About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus &hellip; Continue reading &quot;Arcturus Therapeutics to Present at Upcoming Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-06T13:04:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210106005325r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arcturus Therapeutics to Present at Upcoming Investor Conference\",\"datePublished\":\"2021-01-06T13:04:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\\\/\"},\"wordCount\":384,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210106005325r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\\\/\",\"name\":\"Arcturus Therapeutics to Present at Upcoming Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210106005325r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-01-06T13:04:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210106005325r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210106005325r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arcturus Therapeutics to Present at Upcoming Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arcturus Therapeutics to Present at Upcoming Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\/","og_locale":"en_US","og_type":"article","og_title":"Arcturus Therapeutics to Present at Upcoming Investor Conference - Market Newsdesk","og_description":"Arcturus Therapeutics to Present at Upcoming Investor Conference SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Arcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in a panel discussion taking place at the 13th Annual Biotech Showcase\u2122 Investor Conference: Infectious Disease &#8211;COVID-19 Vaccines: All things impacted by COVID-19: The pursuit for an effective vaccine developed at a pandemic pace Panel Discussion Date: Monday, Jan 11, 2020 Time: 1:00 p.m. ET, on-demand Jan 12-March 31 on the event\u2019s platform, partneringONE Conference Link About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus &hellip; Continue reading \"Arcturus Therapeutics to Present at Upcoming Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-06T13:04:20+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210106005325r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arcturus Therapeutics to Present at Upcoming Investor Conference","datePublished":"2021-01-06T13:04:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\/"},"wordCount":384,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210106005325r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\/","name":"Arcturus Therapeutics to Present at Upcoming Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210106005325r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-01-06T13:04:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210106005325r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210106005325r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-upcoming-investor-conference-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arcturus Therapeutics to Present at Upcoming Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=409412"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409412\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=409412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=409412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=409412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}